Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company is headquartered in Waltham, Massachusetts. Show more
Location: 300 Fifth Avenue, Waltham, MA, 02451, United States | Website: https://crescentbiopharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
214.6M
52 Wk Range
$9.81 - $63.00
Previous Close
$12.79
Open
$12.95
Volume
9,210
Day Range
$12.52 - $13.20
Enterprise Value
54.89M
Cash
152.6M
Avg Qtr Burn
-6.269M
Insider Ownership
10.37%
Institutional Own.
82.11%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
SQ Dalcinonacog alfa (DalcA) Details Hemophilia, Genetic disorder | Failed Discontinued | |
Marzeptacog alfa (MarzAA) Details Hemophilia, Blood disorder, Rare genetic disease | Failed Discontinued |
